(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr22.60 | 3.11% | 16.03% |
| BOIRON (BOI.PA) | €36.02 | 3.04% | 8.64% |
| LNA SANTE (LNA.PA) | €22.55 | 2.54% | 9.08% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
3.11% Forward Dividend Yield and 16.03% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 22.6. Meaning, the purchaser of the share is investing kr22.6 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VISTIN PHARMA’s stock is considered to be oversold (<=20).
More news about VISTIN PHARMA.
2. BOIRON (BOI.PA)
3.04% Forward Dividend Yield and 8.64% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.15. Meaning, the purchaser of the share is investing €13.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.64%.
Moving Average
BOIRON’s value is below its 50-day moving average of €39.45 and way below its 200-day moving average of €44.28.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BOIRON’s stock is considered to be overbought (>=80).
More news about BOIRON.
3. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 9.89. Meaning, the purchaser of the share is investing €9.89 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 732.02M for the twelve trailing months.
Volatility
LNA SANTE’s last week, last month’s, and last quarter’s current intraday variation average was 0.63%, 0.75%, and 1.78%.
LNA SANTE’s highest amplitude of average volatility was 1.54% (last week), 2.07% (last month), and 1.78% (last quarter).
Yearly Top and Bottom Value
LNA SANTE’s stock is valued at €22.55 at 11:30 EST, way under its 52-week high of €34.00 and way above its 52-week low of €19.00.
More news about LNA SANTE.
